Relay Therapeutics Shares Rise After FDA Grants Breakthrough Therapy Status for Zovegalisib-Fulvestrant Regimen
Relay Therapeutics Inc. (NASDAQ: RLAY) saw its stock climb in premarket trading after the U.S. Food and Drug Administration awarded Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for a defined breast cancer population. The decision was supported by Phase 1/2 ReDiscover trial data and covers adults with PIK3CA-mutant…